SchistosomiasisNCT07482215
Prevalence and Molecular Identification of Human Schistosomiasis
An observational study of Schistosomiasis, run by Assiut University.
Trial summary
Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Schistosomiasis
- What is being tested?
- Molecular phylogenetic and haplotype analysis
- How many people
- 359 participants
- Where
- No sites listed yet
- Study dates
- May 2026to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: All participants presented in Assiut Governorate hospitals
Who may be able to join
- Patients aged ≥ 5 years of both sexes attending Assiut Governorate hospitals during the study period.
- Patients clinically suspected of having schistosomiasis (urinary and/or intestinal) or referred for parasitological examination.
- Individuals (or guardians, in case of minors) who provide written informed consent.
- Patients willing to provide the required biological samples (urine and/or stool).
Who cannot join
- Patients Received praziquantel within the last 3 months before sample collection
- Patients with incomplete clinical or epidemiological data.
- Patients refusing participation or sample collection.
- Improperly collected, contaminated, or insufficient samples.
- Patients suffering from severe comorbid conditions that may interfere with the interpretation of results (e.g., advanced hepatic or renal failure).
- children with congenital urinary or intestinal anomalies.
About this study
Official title: Prevalence and Molecular Identification of Human Schistosomiasis With Assessment of Associated Epidemiological Risk Factors in Assiut Governorate, Egypt
Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma
Read the detailed description
Schistosomiasis has been diagnosed in Egypt since pharaonic times (3200 B.C.) by recovering Schistosome eggs and antigens in ancient mummies.In Egypt, Schistosoma mansoni and Schistosoma haematobium have historically been highly endemic, with widespread distribution along the Nile Delta and Valley.(4) Schistosoma haematobium is responsible for urogenital schistosomiasis, with hematuria as its primary manifestation, while Schistosoma mansoni, the prevalent species in Egypt, is causing intestinal schistosomiasis with liver-related sequelae
- Conditions
- Schistosomiasis
- Being tested
- Molecular phylogenetic and haplotype analysis
- Medical subject headings
- Schistosomiasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Molecular phylogenetic and haplotype analysisDiagnostic test
DNA Sequencing and cox1 Gene Analysis of Schistosoma Isolates
| Study group | Role | What they receive |
|---|---|---|
| Schistosoma haematobium | Urine filtration technique (10 ml urine) for diagnosis Receives: Diagnostic Test: Molecular phylogenetic and haplotype analysis | |
| Schistosoma mansoni | Direct wet mount and Kato-Katz thick smear technique (stool) for diagnosis Receives: Diagnostic Test: Molecular phylogenetic and haplotype analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
prevalence of human schistosomiasis in the study participants
using conventional microscopic examination
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2026
- Study startMay 2026 (estimated)
- Primary completionAug 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SchistosomiasisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 359 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Intesar Heshmat Yousef, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07482215
- Sponsor's protocol ID
- PMHS
- Status last verified
- Mar 2026
- First submitted
- 16 Mar 2026
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence and Molecular Identification of Human Schistosomiasis With Assessment of Associated Epidemiological Risk Factors in Assiut Governorate, Egypt
- ClinicalTrials.gov ID
- NCT07482215
- Acronym / sponsor ID
- PMHS
- Conditions
- Schistosomiasis
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 359 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- May 2026 (estimated)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 19 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma
Detailed description
Schistosomiasis has been diagnosed in Egypt since pharaonic times (3200 B.C.) by recovering Schistosome eggs and antigens in ancient mummies.In Egypt, Schistosoma mansoni and Schistosoma haematobium have historically been highly endemic, with widespread distribution along the Nile Delta and Valley.(4) Schistosoma haematobium is responsible for urogenital schistosomiasis, with hematuria as its primary manifestation, while Schistosoma mansoni, the prevalent species in Egypt, is causing intestinal schistosomiasis with liver-related sequelae
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Schistosoma haematobium | – | Diagnostic Test: Molecular phylogenetic and haplotype analysisUrine filtration technique (10 ml urine) for diagnosis |
| Schistosoma mansoni | – | Diagnostic Test: Molecular phylogenetic and haplotype analysisDirect wet mount and Kato-Katz thick smear technique (stool) for diagnosis |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- All participants presented in Assiut Governorate hospitals
Key inclusion criteria (4 listed)
- Patients aged ≥ 5 years of both sexes attending Assiut Governorate hospitals during the study period.
- Patients clinically suspected of having schistosomiasis (urinary and/or intestinal) or referred for parasitological examination.
- Individuals (or guardians, in case of minors) who provide written informed consent.
- Patients willing to provide the required biological samples (urine and/or stool).
Key exclusion criteria (6 listed)
- Patients Received praziquantel within the last 3 months before sample collection
- Patients with incomplete clinical or epidemiological data.
- Patients refusing participation or sample collection.
- Improperly collected, contaminated, or insufficient samples.
- Patients suffering from severe comorbid conditions that may interfere with the interpretation of results (e.g., advanced hepatic or renal failure).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Molecular phylogenetic and haplotype analysisDNA Sequencing and cox1 Gene Analysis of Schistosoma Isolates | Diagnostic test | Schistosoma haematobium, Schistosoma mansoni |
Primary outcome
prevalence of human schistosomiasis in the study participants
Time frame: 24 hours
using conventional microscopic examination
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
Related trials for Schistosomiasis
Not yet recruitingPhase 3
A Phase III Trial to Evaluate the Safety and Efficacy of Anti-inflammatory Drugs in Addition to Praziquantel in Girls and Women With Female Genital Schistosomiasis
Female Genital Schistosomiasis
Not yet recruitingPhase 2/3
Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis
Schistosomiasis, Schistosoma Mansoni
Not yet recruiting
Assessment of Right Ventricular-Pulmonary Arterial Coupling in Schistosomiasis-Associated Pulmonary Arterial Hypertension
Schistosomiasis
Recruiting
Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations
Onchocerciasis (River Blindness), Schistosomiasis
Not yet recruitingObservational study
Nanobody-based Schistosomiasis Urine Test Kit Research
Schistosomiasis Haematobia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Schistosomiasis, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
prevalence of human schistosomiasis in the study participants (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.